Medigene AG: Medigene announces formation of new Scientific Advisory Board

Planegg (pta006/08.08.2017/07:30 UTC+2) Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced the appointment of eight leading experts to its new immuno-oncology-focused Scientific Advisory Board (SAB). The SAB will consult the company with regard to strategic options and future perspectives within its research and development activities. The SAB will thereby further strengthen Medigene's leadership position in the development of innovative cancer immunotherapies.

The inaugural members of Medigene's new Scientific Advisory Board are: The Chairman, Prof. Dr. Ernst-Ludwig Winnacker, (Co-founder of Medigene, Professor emeritus at the University of Munich, Department of Biochemistry, former President of the German Research Foundation, former Secretary-General of the European Research Council (ERC), Brussels, former Secretary General of the Human Frontier Science Program in Strasbourg) and the following members:

Dr. Micha Drukker: Leader of the research group "Human Pluripotent Stem Cell Lineage Choice" and head of the core facility "Human Induced Pluripotent Stem Cells" at the Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Munich/Neuherberg, Germany

Prof. Dr. med. Irmela Jeremias: Group Leader at the Research Unit Gene Vectors, Haematologikum, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Munich, Germany

Prof. Dr. Peter H. Krammer: Head of the Division of Immunogenetics in the Tumor Immunology Program at the German Cancer Research Center (DKFZ) and member of the Board of Directors of the National Center for Tumor Diseases (NCT) in Heidelberg, Germany

Dr. Manfred Rüdiger: Former CEO of Kiadis Pharma, international experienced life science industry expert, held various executive positions in different companies during last two decades

Dr. Lawrence E. Samelson: Senior Investigator, CCR Deputy Director, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

Prof. Dr. Freda Stevenson: Professor of Immunology within Medicine at the University of Southampton, UK

Prof. Dr. Jolanda de Vries: Professor of Immunology within the Department of Tumor Immunology at the Nijmegen Centre for Molecular Life Sciences, The Netherlands

"It is a great pleasure to announce the formation of our excellent new Scientific Advisory Board at Medigene," said Prof. Dolores Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene AG. "The diverse expertise in immunology, gene therapy, cancer and stem cell research present in this board will support our ongoing and future development activities in cancer immunotherapies. We aim to tap the profound knowledge of these individuals and their vast networks to challenge, support and advise Medigene."

For more information and short CVs of the members of the Scientific Advisory Board, please visit Medigene's website: www.medigene.com/company/sab

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene focuses on the development of personalized T cell-based therapies, with projects currently in preclinical and clinical development.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 200033-3301
E-Mail:	public.relations@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate